Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05938036 · ClinicalTrials.gov registry record · Phase 2
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
A Phase 2 study of Acute Respiratory Distress Syndrome (ARDS), sponsored by Aqualung Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05938036: Active Phase 2 study of Acute Respiratory Distress Syndrome (ARDS), sponsored by Aqualung Therapeutics.
NCT05938036 is a Phase 2 study of Acute Respiratory Distress Syndrome (ARDS) that is active but no longer recruiting, run by Aqualung Therapeutics. The registered enrollment target is 15 participants, below the 17,733-participant average among 8 other Acute Respiratory Distress Syndrome (ARDS) trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05938036, a Phase 2 study of Acute Respiratory Distress Syndrome (ARDS), is active but no longer recruiting, sponsored by Aqualung Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.
Primary Outcome
Assessment will be done by measuring the following parameter: • Incidence and severity of treatment-emergent adverse events (TEAEs) from Day 1 to end of study (EOS).
Conditions Studied
Interventions
- DRUG ALT-100 mAb
- DRUG ALT-100 (Placebo)
Study Locations (1)
Arizona
- Banner University of Arizona - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
What the registry record for NCT05938036 still lists
NCT05938036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 17,733-participant average among 8 other Acute Respiratory Distress Syndrome (ARDS) trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Acute Respiratory Distress Syndrome (ARDS) appearing as the primary indexed condition, and to 2 interventions - of which ALT-100 mAb is the first listed.
NCT05938036 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05938036 about?
NCT05938036 is a clinical study titled "Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS". A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.
What is the current status of trial NCT05938036?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-12-01. Estimated completion is 2027-07-01.
What conditions does trial NCT05938036 study?
This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome (ARDS).
What interventions are being tested in trial NCT05938036?
The interventions under investigation include: ALT-100 mAb (DRUG), ALT-100 (Placebo) (DRUG).
Who is sponsoring clinical trial NCT05938036?
This trial is sponsored by Aqualung Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05938036 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Distress Syndrome (ARDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05938036's enrollment target sits among peer trials
15 9th of 8 the lowest of 8 other Acute Respiratory Distress Syndrome (ARDS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Respiratory Distress Syndrome (ARDS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RECRUITING · Phase 2
-
Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
RECRUITING · Phase 2
-
An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI